Your search for smoking cessation returned 184 results

Par’s generic version of Chantix is currently the only available one in the US.

The recalled lots of Chantix were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from May 2019 to September 2021.

To date, the Company has not received any reports of adverse events related to this recall.

N-nitroso-varenicline may be associated with an increased cancer risk based on data from closely related nitrosamine compounds.

Significantly fewer adverse reactions reported by those in the cytisine group versus the varenicline group.

This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there’s updates to the cancer drug Keytruda.

Long-term use of a product containing N-nitroso-varenicline may be associated with an increased cancer risk based on data from closely related nitrosamine compounds.

Recommendations include diagnostic workup to define stroke etiology to reduce risk for recurrent stroke

High quality communication in tobacco treatment programs with lung cancer screenings was significantly associated with self-efficacy for smoking cessation.

Guideline offers simple practice changes that may increase effectiveness of tobacco-dependence pharmacotherapy.